Researchers analyzed the enhancement of the anticancer effect of tumor necrosis factor-related apoptosis-inducing ligand by paclitaxel, cabazitaxel and docetaxel in the whole population of PC3 and DU145 prostate cancer cells, but also in CD44+/CD24− prostate cancer stem cells. [Int J Mol Sci]
Full Article

Twenty-two 3-O-substituted-3′,4′,5′-trimethoxyflavonols have been designed and synthesized for their anti-proliferative activity towards three human prostate cancer cell lines. The authors indicated that most of them are significantly more potent than the parent 3′,4′,5′-trimethoxyflavonol in inhibiting the cell proliferation in PC-3 and LNCaP prostate cancer cell models. [Bioorg Med Chem]
Abstract

The authors investigated the effect of atorvastatin on HIF-1α expression and radiosensitivity of prostate cancers cells. Astorvastatin reduced the HIF-1α protein expression in hypoxia-induced PC3 cells, and induced apoptosis of both control and hypoxia-induced cells with and without irradiation. [Biosci Rep]
Abstract | Full Article

Scientists highlight what is currently known about tumor organoid culture, the advantages and challenges of the model system, compare it with other pre-clinical cancer models, and evaluate its value for drug development. [Cell Chem Biol]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the prostate cell research field.

Advaxis, Inc. announced three abstracts were selected for presentation. [Press release from Advaxis, Inc. discussing research to be presented at the 2017 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, Mainz/Frankfurt]
Press Release

Madison Vaccines Incorporated announced that the first patient has been dosed in an expanded clinical trial to further extend the potential benefits of checkpoint inhibitors to men with advanced prostate cancer. [Madison Vaccines Incorporated]
Press Release

MilliporeSigma, a subsidiary of pharmaceutical giant Merck KGaA of Darmstadt, Germany, has become a new major player in the complicated European patent battles over CRISPR, the revolutionary genome-editing tool. [ScienceInsider]
Editorial

A Chinese biologist whose team retracted a high-profile paper on a gene-editing technology has vowed to press ahead with experiments that he hopes will vindicate the potential rival to the CRISPR/Cas9 system. [ScienceInsider]
Editorial

The Senate has voted in quick succession to pass bills reauthorizing the FDA to collect fees from the industry and expanding access to unapproved medicines. President Trump is set to sign the user fee bill into law, while the right-to-try legislation will go to the House. [FierceBiotech]
Editorial

An Iranian disaster-medicine researcher who was sent to prison in April 2016 is due to go to trial, on charges of “collaboration with a hostile government”. Ahmadreza Djalali has been warned by the Iranian court that he may be facing a death sentence, according to his wife, Vida Mehrannia. [Nature News]
Editorial

Princess Sumaya bint El Hassan successfully lured the high-profile biennial conference to the Middle East for the first time — part of Jordan’s ongoing push to transform itself into a regional research powerhouse. The country hopes to emphasize the power of science to transcend politics and war in the increasingly volatile Middle East. [Nature News]
Editorial